Why Most Commercialization Readiness Reviews Happen Too Late to Matter

There's a specific kind of meeting that happens in tech transfer offices across the country. Someone calls it a "commercialization readiness review." The research team shows up with a polished deck. The TTO staff ask about IP status, market size, and competition. Everyone nods. Then the meeting ends, nothing changes, and eighteen months later the opportunity is gone.

Photo by Kampus Production on Pexels.

The ritual feels productive. The outcome rarely is.

The core problem is timing. Most readiness reviews happen after a patent has been filed and before a licensing conversation begins. That sounds logical until you realize the decisions that most shape commercial outcomes were made years earlier: how the research was scoped, which applications were pursued, what data was collected (and what wasn't), whether industry contacts were cultivated. By the time the review meeting happens, the technology's commercial trajectory is already largely fixed.

Reviewing readiness after the fact is a bit like inspecting a building's foundation after the walls go up. You can see problems clearly. You cannot do much about them.

What readiness actually requires

Commercial readiness isn't a status. It's a set of specific, answerable questions that need to be asked at multiple points during the research lifecycle, not just once at the end.

Those questions break down roughly like this:

graph TD
    A[Early Research Stage] --> B{Is the application space defined?}
    B -->|No| C[Reframe research objectives with market input]
    B -->|Yes| D[Mid-Stage: Is enabling data being captured?]
    D -->|No| E[Add data collection protocols now]
    D -->|Yes| F[Pre-Filing: Are claim boundaries commercially meaningful?]
    F --> G[Post-Filing Readiness Review]

Each gate asks a fundamentally different question. Early on, the question is about application framing. Mid-stage, it's about data sufficiency. Pre-filing, it's about whether the IP being created actually covers what a licensee would need to practice the technology. A single end-stage review collapses all of these into one conversation that can't possibly address any of them properly.

The data problem nobody mentions

Here's something that comes up repeatedly when deals fall apart in due diligence: the data a company needs to make a licensing decision wasn't the data a researcher needed to publish a paper.

Publications optimize for novelty and statistical significance. Licensing conversations require proof of concept at scale, safety profiles, manufacturing feasibility signals, or performance benchmarks that match real-world use conditions. These are different experiments. Running them as an afterthought, post-publication, is expensive and slow. Running them as part of the original research design costs almost nothing extra, assuming someone flagged the need early enough.

Readiness reviews that happen at the end have no ability to influence this. The experiments are done. The publications are written. The data that would have been useful simply doesn't exist.

Who should be in the room (and when)

The standard readiness review involves TTO staff and the PI. Occasionally a business development person. Rarely someone with direct industry operating experience in the relevant sector.

That composition makes sense for a compliance checkpoint. For a genuine commercialization assessment, it's incomplete. Someone who has actually licensed technology in the target industry, or built a company around a similar platform, will immediately spot gaps that everyone else in the room normalizes because they've never seen it done differently.

Earlier involvement from people with that kind of experience changes what gets built, not just how it gets packaged afterward. Several universities have started embedding industry liaison roles inside research groups working in high-priority sectors. The ones doing it seriously report that the quality of licensing conversations improves substantially, because the data and IP are structured from the start to support them.

A small shift with large consequences

None of this requires reinventing the TTO. It requires adding two or three structured touchpoints earlier in the research lifecycle, with a short checklist focused on commercial data needs, application framing, and IP scope. It requires having someone in those early conversations who can ask the questions a potential licensee would ask.

And it requires accepting that a readiness review conducted after filing is mostly a documentation exercise. Useful for records. Not useful for changing outcomes.

The window where these interventions matter is earlier than most offices operate. That window closes quietly, without announcement, while everyone is focused on what they can still see.